DYNACIRC CR Drug Patent Profile

✉ Email this page to a colleague

When do Dynacirc Cr patents expire, and what generic alternatives are available?

Dynacirc Cr is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in DYNACIRC CR is isradipine. There are seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the isradipine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Dynacirc Cr

A generic version of DYNACIRC CR was approved as isradipine by WATSON LABS TEVA on January 5^th, 2006.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for DYNACIRC CR?
What are the global sales for DYNACIRC CR?
What is Average Wholesale Price for DYNACIRC CR?

Summary for DYNACIRC CR

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	119
Clinical Trials:	3
Patent Applications:	5,704
DailyMed Link:	DYNACIRC CR at DailyMed

Drug patent expirations by year for DYNACIRC CR

Recent Clinical Trials for DYNACIRC CR

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Texas at Austin	Early Phase 1
National Institute on Drug Abuse (NIDA)	Early Phase 1
Northwestern University Dixon Fund	Phase 2

See all DYNACIRC CR clinical trials

US Patents and Regulatory Information for DYNACIRC CR

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for DYNACIRC CR

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-002	Jun 1, 1994	⤷ Sign Up	⤷ Sign Up
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994	⤷ Sign Up	⤷ Sign Up
Glaxosmithkline Llc	DYNACIRC CR	isradipine	TABLET, EXTENDED RELEASE;ORAL	020336-001	Jun 1, 1994	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for DYNACIRC CR

See the table below for patents covering DYNACIRC CR around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Ireland	56515	OSMOTIC DEVICE WITH DUAL THERMODYNAMIC ACTIVITY	⤷ Sign Up
Canada	1317550	FORME POSOLOGIQUE D'UN MEDICAMENT POUR LE TRAITEMENT DES MALADIES CARDIO-VASCULAIRES (DOSAGE FORM FOR TREATING CARDIOVASCULAR DISEASES)	⤷ Sign Up
Australia	6460380		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for DYNACIRC CR

Recent Clinical Trials for DYNACIRC CR

Make Better Decisions: Try a trial or see plans & pricing